{"entity":{"id":"fgg","kind":"target","name":"FGG","aka":["fibrinogen gamma chain","Fibrinogen gamma chain"],"tldr":"FGG (Fibrinogen gamma chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerises to form an insoluble fibrin matrix. Has a major function in haemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilise the lesion and guide cell migration during re-epithelialisation.\n\nOpen Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.43, affected pathway 0.97, literature 0.84, genetic association 0.24, animal model 0.38).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3694","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3694"},{"label":"UniProt P02679","url":"https://www.uniprot.org/uniprotkb/P02679/entry"},{"label":"NCBI Gene 2266","url":"https://www.ncbi.nlm.nih.gov/gene/2266"},{"label":"Ensembl ENSG00000171557","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171557"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.43. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGG","role":["drug-target"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3694","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3694","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P02679","url":"https://www.uniprot.org/uniprotkb/P02679/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000171557","url":"https://platform.opentargets.org/target/ENSG00000171557/associations","note":"association with cancer (MONDO_0004992) 0.68;  (GraphQL API, CC0)"}],"hgnc":"HGNC:3694","ensembl":"ENSG00000171557","uniprot":"P02679","entrez":"2266","biology":"Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerises to form an insoluble fibrin matrix. Has a major function in haemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilise the lesion and guide cell migration during re-epithelialisation. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Location: Secreted (UniProt). Locus 4q32.1 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/fgg/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}